Company Overview - GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on treating inflammatory, fibrotic, and autoimmune diseases through innovative therapies targeting Natural Killer T (NKT) cells [2] - The company's lead program, GRI-0621, is an inhibitor of invariant NKT (iNKT) cell activity, being developed as an oral therapeutic for idiopathic pulmonary fibrosis, addressing a significant unmet medical need [2] - GRI Bio is also developing a pipeline of diverse NKT (dNKT) agonists for systemic lupus erythematosus and has a library of over 500 proprietary compounds to support its growing pipeline [2] Recent Developments - On March 10, 2025, GRI Bio received notice from Nasdaq confirming that it has regained compliance with the minimum bid price rule, which is crucial for maintaining its listing on the exchange [1]
GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule